Necitumumab (Portrazza)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2016-02-15: Initial authorization for the treatment of squamous non-small cell lung cancer.
  • 2021-02-18: Authorization withdrawn at the request of the manufacturer, for commercial reasons

History of changes in Health Canada indication

  • 2017-03-16: Initial notice of compliance

History of changes in PMDA indication

Also known as

  • Code name: IMC-11F8
  • Brand name: Portrazza